Department of Biotechnology and Enzyme Science, Institute of Food Science and Biotechnology, University of Hohenheim, Garbenstr. 25, 70599 Stuttgart, Germany.
Nutrients. 2022 Jun 24;14(13):2621. doi: 10.3390/nu14132621.
A new diamine oxidase (DAO-1) was discovered recently in the yeast PO1f and investigated for its histamine degradation capability under simulated intestinal conditions. DAO-1 was formulated together with catalase as a sucrose-based tablet. The latter (9 × 7 mm; 400 mg) contained 690 nkat of DAO-1 activity, which was obtained from a bioreactor cultivation of a genetically modified with optimized downstream processing. The DAO-1 tablet was tested in a histamine bioconversion experiment under simulated intestinal conditions in the presence of food constituents, whereby about 30% of the histamine was degraded in 90 min. This amount might already be sufficient to help people with histamine intolerance. Furthermore, it was found that the stability of DAO-1 in a simulated intestinal fluid is influenced distinctively by the presence of a food matrix, indicating that the amount and type of food consumed affect the oral supplementation with DAO. This study showed for the first time that a microbial DAO could have the potential for the treatment of histamine intolerance by oral supplementation.
最近在酵母 PO1f 中发现了一种新的二胺氧化酶(DAO-1),并在模拟肠道条件下研究了其组胺降解能力。DAO-1 与过氧化氢酶一起配制成基于蔗糖的片剂。后者(9×7 毫米;400 毫克)含有 690 nkat 的 DAO-1 活性,这是从经过遗传修饰的生物反应器培养物中获得的,优化了下游处理。在含有食物成分的模拟肠道条件下的组胺生物转化实验中测试了 DAO-1 片剂,在 90 分钟内降解了约 30%的组胺。这一数量可能已经足以帮助那些患有组胺不耐受症的人。此外,还发现 DAO-1 在模拟肠液中的稳定性受到食物基质的显著影响,这表明所消耗的食物数量和类型会影响 DAO 的口服补充。这项研究首次表明,微生物 DAO 有可能通过口服补充来治疗组胺不耐受症。